Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510198 · ClinicalTrials.gov registry record · NA
Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Terminated
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT00510198 is a NA study that was terminated before completion, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 120 participants.
The verdict
NCT00510198, a NA study, was terminated before completion, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- TERMINATED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of the PRECEDE-HF study is to collect data to compare patients whose heart failure is managed using Cardiac Compass with OptiVol (which is a tool in the device that records information about the heart that doctors can use to help treat their heart disease) combined with standard treatment methods (Access Group) to patients whose heart failure is managed by standard treatment methods only (Control Group). This comparison will show if the additional monitoring provided by Cardiac Compass with OptiVol delays the time patients are first admitted to hospital for heart failure or delays the time to death.
Interventions
- DEVICE Cardiac Compass with OptiVol Fluid Status Monitoring
- DEVICE Standard of Care alone (clinical assessment)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510198
The ClinicalTrials.gov registry entry for NCT00510198 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cardiac Compass with OptiVol Fluid Status Monitoring is the first listed.
NCT00510198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00510198 about?
NCT00510198 is a clinical study titled "Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure". The purpose of the PRECEDE-HF study is to collect data to compare patients whose heart failure is managed using Cardiac Compass with OptiVol (which is a tool in the device that records information about the heart that doctors can use to help treat their heart disease) combined with standard treatmen...
What is the current status of trial NCT00510198?
This trial is currently terminated. It is a NA study. The enrollment target is 120 participants. The study started on 2007-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00510198?
The interventions under investigation include: Cardiac Compass with OptiVol Fluid Status Monitoring (DEVICE), Standard of Care alone (clinical assessment) (DEVICE).
Who is sponsoring clinical trial NCT00510198?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.